ALKS 3831 is composed of samidorphan, a new, potent mu-opioid antagonist, in combination with an antipsychotic drug, olanzapine. The trial is designed to evaluate the efficacy, safety and
The US Food and Drug Administration (FDA) has recently approved Northera to treat NOH, a disorder caused by an underlying neurologic disease. Currently, the norepinephrine pro-drug Northera is
Both SLE and LN represent an area of high unmet medical need, where new therapies are essential. SLE is an autoimmune disease, where the immune system produces proteins
CureXcell is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. A total of 280 patients
The NDA is based on the results of two Phase III clinical trials that met their primary endpoints. The 12-week efficacy portion of the trials showed significant superiority
Ozurdex is approved for treatment of DME patients who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroids therapy.
By using the new technology, doctors will be able to quickly diagnose the virus. Professor Jiro Yasuda was quoted by AFP as saying that the new method is
If approved, Nuplazid will establish a new and distinctly different pharmacological approach to treat psychosis. The company has already completed a pivotal Phase III trial of Nuplazid in
The COMET-1 trial evaluated cabozantinib in mCRPC patients whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial failed to meet its primary
APD811 is an investigational drug candidate internally discovered and developed by Arena for the treatment of vasospastic diseases, such as PAH. Arena Operations Global Regulatory Affairs senior vice-president
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.